Defining optimal therapy for muscle invasive bladder cancer.
OBJECTIVE
We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy.


METHODS
We reviewed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. We analyzed all cohort, phase II and randomized phase III studies providing level 1 to 3 evidence impacting survival.


RESULTS
Cisplatin based chemotherapy combined with high quality radical cystectomy and complete pelvic lymph node dissection improves survival over that of cystectomy alone. Surgery quality is an important predictor of survival even in patients receiving chemotherapy. Neoadjuvant chemotherapy is favored over adjuvant chemotherapy because it is better tolerated and more patients are able to receive effective therapy before rather than after surgery.


CONCLUSIONS
Neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection is the optimal curative strategy in most patients presenting with muscle invasive bladder cancer.
Herr
Harry W
HW
Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA. herrh@mskcc.org
Dotan
Zohar
Z
Donat
S Machele
SM
Bajorin
Dean F
DF
D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D006801:Humans; D009130:Muscle, Smooth; D009361:Neoplasm Invasiveness; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy*